- Tryp Therapeutics is a development-stage pharmaceutical company dedicated to finding novel bioscience solutions for conditions with unmet needs
- The company’s executive team will present an overview of its Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program, in response to conditions such as fibromyalgia, at next month’s Ladenburg Thalmann Healthcare Conference
- Tryp’s synthetic psychedelic drug candidate will be further developed in an upcoming phase 2a clinical study in partnership with pediatric eating disorders expert Jennifer Miller, M.D. at the University of Florida
- The trial will focus on Tryp’s flagship candidate, TRP-8802, in treating binge eating and hypothalamic obesity
- The company expects to begin manufacturing its initial oral psilocybin formulation in September
Bio-pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) will present an overview of Tryp’s efforts to develop a novel psychedelic drug candidate for treating fibromyalgia and other neuropsychiatric-based disorders at the annual Ladenburg Thalmann Healthcare Conference next month.
Ladenburg Thalmann & Co. Inc. is an experienced provider of investment banking and capital markets products and services. The Ladenburg Thalmann Healthcare Conference is a well-respected event for investors who are specifically focused on healthcare and life sciences companies, and will be held virtually on July 13 and 14, with Tryp’s presentation taking place July 13 at 3 p.m. EDT (https://nnw.fm/xyiS1).
In 2021, fibromyalgia remains an elusive medical condition difficult to verify and treat 45 years after it was first used as a term to describe century-old observations of patients’ complaints of chronic widespread pain and fatigue.
The first clinical, controlled study of fibromyalgia symptoms was only published as recently as 1981 and trials for the first proposed medications to treat it were subsequently announced in 1986. At present, all forms of diagnosis involve first ruling out other potential causes and verifying that a set number of symptoms exist, and the challenge of treating it results in a range of recommendations from “getting enough sleep and exercise” to using opioid pain drugs (https://nnw.fm/XKS0o).
Efforts to diagnose fibromyalgia and consequently treat it may be improved thanks to numerous ongoing efforts to develop a blood test that will recognize its presence. In May, researchers at the Ohio State University Wexner Medical Center claimed to have developed the first potentially successful blood test for diagnosing fibromyalgia, according to media reports (https://nnw.fm/i0Qph).
Tryp is developing its lead drug candidate, TRP-8802, as a potentially novel drug class solution for treating certain neuropsychiatric-based disorders such as fibromyalgia, utilizing psychedelic substances tested under its Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program.
Tryp’s mission is to use its novel solutions, including the PFN program, to develop compounds for treating diseases with high unmet medical needs.
The company is also in the process of launching a Phase 2a clinical study using its TRP-8802 synthetic psilocybin Active Pharmaceutical Ingredient (“API”) to test for treatment of binge eating and hypothalamic obesity in partnership with pediatric eating disorders expert Jennifer Miller, M.D. and her team at the University of Florida.
Tryp expects to manufacture its initial batch of orally available cGMP psilocybin API in September, which will then be analyzed for quality consistency to establish the final formulation of the oral psilocybin product.
The company’s executive team will discuss the company’s business and its pipeline at the Ladenburg Thalmann Healthcare Conference and then participate in a brief analyst-led discussion.
Registration for the virtual event can be completed online at https://nnw.fm/lcCzV
For more information, visit the company’s website at www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://nnw.fm/TRYPF
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork.
